Bafna Pharmaceuticals Ltd (BAFNAPH) is currently trading at 449.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Bafna Pharmaceuticals Limited is an Indian generic pharmaceutical manufacturer and exporter that develops and produces finished dosage formulations, operating EOU and regulated-market compliant facilities in Chennai with product registrations across regulated and emerging markets and historical accreditations including UK-MHRA and Australia TGA. The company reported a sharp sequential revenue contraction in Q1 FY27: Revenue from operations fell to INR 2,658.32 lakhs from INR 4,223.93 lakhs in Q4 FY26, while profit before tax compressed to only INR 7.51 lakhs, highlighting quarter-to-quarter volatility and margin pressure driven by sales mix, inventory movements, and cost absorption issues. Operationally Bafna has focused on regulatory compliance and export readiness: in 2026 it hived off the Madhavaram manufacturing unit and established a granulation facility at Grant Lyon to support regulated-market supplies and complex formulations, signalling a strategic pivot to validated manufacturing and higher‑compliance markets. The company faces contingent tax exposure from GST demands totalling INR 235.47 lakhs and INR 331.09 lakhs (the latter stayed by the Madras High Court), and management states confidence in prevailing on appeal; this remains a material near-term legal and cash‑flow uncertainty that investors should monitor.

Over the past 52 weeks, Bafna Pharmaceuticals Ltd has traded between a low of ₹95.00 and a high of ₹487.45. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Bafna Pharmaceuticals Ltd has a market capitalization of approximately 1,064.18. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Bafna Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 136.61 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,064.18 Cr, Bafna Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Bafna Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Bafna Pharmaceuticals Ltd is 136.61. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.